• Explore /
  • Poster
  • / Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors.

Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors.

Abstract Poster

Authors

null

Luis Teixeira

Service d’Oncologie Médicale, Hôpital Saint-Louis, APHP, Paris Diderot University, Paris, France

Luis Teixeira , Jacques Medioni , Ludovic Doucet , Stephane Culine , Stephane Oudard , Olivier Adotevi , Marie-Agnès Dragon Durey , Jean-Jacques Kiladjian , Mara Brizard , Ludovic Bourré , Simon Wain-Hobson , Rémy DeFrance , Thierry Huet , Pierre Langlade-Demoyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT02301754

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3087)

DOI

10.1200/JCO.2017.35.15_suppl.3087

Abstract #

3087

Poster Bd #

182

Abstract Disclosures

Similar Posters

First Author: Wang Yk

First Author: Thehang H. Luu

First Author: Chia-Chi Lin

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang